

Intrasense publishes H1 2026 results and accelerates its strategic refocusing on artificial intelligence in oncology

- Revenue down 59.3% compared with H1 2025, in a period of transformation marked by the proposed disposal of the Myrian® business and the Company's reorganization
- Strategic refocusing on DUOnco™ Pancreas and DUOnco™ Unity, alongside the phased discontinuation of Myrian®, Liflow®, DUOnco™ Liver and DUOnco™ Bone
- Continued adjustment of the cost base to reflect the Company's level of activity and strategic priorities
- Priority given to the commercial roll-out of DUOnco™ Pancreas and DUOnco™ Unity, now at the heart of Intrasense's strategy

Montpellier, France, 28 September 2026, at 5:45 pm CET. Intrasense (ISIN: FR0011179886 – Ticker: ALINS), [a French specialist in medical imaging and artificial intelligence solutions](#), today announces its half-year results for the six months ended 30 June 2026. These financial statements were approved by the Board of Directors on 28 September 2026.

Half-year activity impacted by the ongoing transformation

Revenue for H1 2026 amounted to €646k, compared with €1,585k in H1 2025. All revenue generated during the period came from the Myrian business. The decline in H1 2026 activity was mainly attributable to the loss of a major maintenance contract in France, delays to several license upgrade projects and timing effects in international markets. This performance reflects the Company's ongoing reorganization and the proposed disposal of the Myrian® business, which required significant management and employee resources and contributed to delays in several commercial opportunities.

Key Figures

€k	H1 2026	H1 2025
Revenue	646	1 585
EBITDA	(4 474)	(2 355)
Operating result	(6 347)	(2 717)
Net result	(6 365)	(2 596)
Shareholders' equity	(12 822)	(6 457)
Cash and cash equivalents	1 012	797

In H1 2026, Intrasense continued to implement the restructuring plan initiated at the end of 2025, following approval of the employment safeguard plan in March 2026.

The initial measures were accompanied by actions to control external expenditure and prioritize investment, with the aim of sustainably aligning the Company's cost base with its level of activity and strategic priorities.

This repositioning phase continues to involve a significant level of operating expenses, notably due to the investments required for the technological, regulatory and commercial development of its AI solutions.

Excluding exceptional restructuring costs, personnel and external expenses decreased by 17% compared with H1 2025. Purchases consumed also decreased to €182k from €287k a year earlier. These changes reflect the initial impact of the organizational adjustment and cost-control measures implemented by the Company.

EBITDA stood at -€4,474k, compared with -€2,355k in H1 2025. This change mainly reflects the low level of activity during the period and the costs associated with the Company's transformation. Other operating income and expenses amounted to -€421k, compared with +€1,206k in H1 2025, due to the combined effect of lower capitalized production and a clean-up of aged invoices for which provisions were reversed.

As at 30 June 2026, Intrasense's gross cash position stood at €1,012k, compared with €797k at 31 December 2025, supported by current-account advances provided by Guerbet¹.

In addition, Intrasense has completed the repayment of its State-guaranteed loans (PGE), with the final instalment paid in June 2026. The *PGE Resilience* loans remain under repayment, according to a schedule running until December 2028.

Strategic review of the product portfolio

Following the abandonment, announced on 3 August 2026, of the proposed disposal of the Myrian® business to EDL, Intrasense conducted a review of its product portfolio and strategic priorities².

Following this review, the Company decided to refocus its strategy and resources on DUOnco™ Pancreas and DUOnco™ Unity, which now form the core of its positioning in artificial intelligence applied to oncology³.

As part of this refocusing, Intrasense has decided to begin the phased discontinuation ("End of Life") of Myrian®, Liflow®, DUOnco™ Liver and DUOnco™ Bone.

The Company will support its customers and partners throughout this transition period, in accordance with its regulatory and contractual commitments.

¹ See press release dated 19 June 2026 – Extension of the maturity date of the shareholder current-account advances agreed with Guerbet on 1 October 2024 and 7 February 2025, and execution of a new €2 million shareholder current-account advance agreement

² See press release dated 3 August 2026 – Abandonment of the proposed disposal of the Myrian® business to EDL.

³ See press release dated 15 September 2026 – Intrasense begins the phased discontinuation ("End of Life") of Myrian®, Liflow®, DUOnco™ Liver and DUOnco™ Bone, and launches a new workforce adjustment plan.

Continued adjustment of the cost base

In September 2026, Intrasense also announced the launch of a new workforce adjustment plan, consistent with the phased discontinuation of certain activities and the concentration of resources on DUOnco™ Pancreas and DUOnco™ Unity. This new restructuring plan is expected to be implemented by the end of 2026³.

Strategic refocusing on DUOnco™ Pancreas and DUOnco™ Unity

During H1 and since the period-end, Intrasense has continued to execute its roadmap for artificial intelligence applied to oncology, with two major regulatory milestones for DUOnco™ Pancreas and DUOnco™ Unity.

- **DUOnco™ Pancreas receives regulatory approval in Japan**

Developed in partnership with Guerbet, DUOnco™ Pancreas is an artificial intelligence solution designed to detect suspicious cancerous or pre-cancerous lesions on CT scans.

The solution received regulatory approval in Japan in June 2026, enabling the Company to take a further step in its international deployment strategy⁴.

This certification complements the CE marking obtained in Europe and paves the way for the commercial roll-out of DUOnco™ Pancreas in Japan.

- **DUOnco™ Unity obtains CE marking under the MDR**

On 21 August 2026, Intrasense announced that DUOnco™ Unity had obtained CE marking⁵.

This multi-organ artificial intelligence solution is designed for oncology monitoring using chest, abdominal and pelvic (CAP) CT scans. It is intended to assist radiologists in the detection, segmentation and longitudinal monitoring of lesions.

Obtaining this certification enables the commercial roll-out of DUOnco™ Unity in Europe and represents an important milestone in the Company's technological and regulatory roadmap.

After several years of technological and regulatory investment, the priority is now to translate these advances into commercial deployments. Intrasense intends to accelerate the development of its distribution channels, notably leveraging its partnerships with Guerbet and other players in its ecosystem, in order to progressively generate orders and recurring revenue from DUOnco™ Pancreas and DUOnco™ Unity.

2026 is a transition year for Intrasense, in the context of a transformation of its product portfolio and organizational adjustment. H2 activity will still include the Myrian® business, while the commercial contribution of the DUOnco™ solutions is expected to be reflected primarily in the signing of framework agreements, order intake and the installation of pilot sites.

⁴ See press release dated 8 June 2026 – Intrasense and Guerbet announce PMDA certification in Japan for DUOnco™ Pancreas, an AI software solution designed to support the analysis of pancreatic regions on contrast-enhanced CT scans.

⁵ See press release dated 21 August 2026 – DUOnco™ Unity, first CE-certified multi-organ AI solution for cancer monitoring on CT scans.

About Intrasense

A French medical imaging specialist since 2004 and the digital subsidiary of the Guerbet Group since 2023, Intrasense designs medical imaging software solutions enhanced by artificial intelligence, with a strategic focus on AI applied to oncology.

Intrasense's product portfolio includes:

- **DUOnco™**, a range of AI algorithms specialized in oncology, notably for pancreatic lesion detection and oncology monitoring.
- **Myrian®** (in the "End of Life" process), an advanced visualization platform equipped with cutting-edge clinical tools that simplifies the interpretation of all types of images.
- **Liflow®** (in the "End of Life" process), a solution dedicated to the longitudinal monitoring of cancer patients.

By combining clinical expertise and operational performance, Intrasense provides healthcare professionals with high-value medical tools that facilitate analysis, diagnosis and patient management.

More information at www.intrasense.fr

Contacts

SEITOSEI.ACTIFIN

Analyst & Investor Relations

Foucauld Charavay
Tel.: +336 37 83 33 19
intrasense@seitosei-actifin.com

Press Relations

Isabelle Dray
Tel. : +33 6 85 36 85 11
isabelle.dray@seitosei-actifin.com